Stockholders’ Deficit (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 15, 2025 |
Sep. 29, 2025 |
Jul. 02, 2025 |
May 12, 2025 |
Aug. 06, 2024 |
Apr. 29, 2024 |
Nov. 30, 2025 |
Sep. 30, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Oct. 16, 2025 |
Oct. 15, 2025 |
Aug. 07, 2025 |
Apr. 21, 2025 |
Nov. 02, 2018 |
|||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Capital stock par value | $ 0.001 | ||||||||||||||||
| Common stock, shares authorized | 1,000,000,000 | 1,000,000,000 | 1,000,000,000 | 100,000,000 | 100,000,000 | ||||||||||||
| Preferred stock, shares authorized | 5,000,000 | 5,000,000 | 5,000,000 | ||||||||||||||
| Redeemable common stock | $ 1,228 | ||||||||||||||||
| Right to appoint board of directors description | Pursuant to the Membership Interest Purchase Agreement, so long as DNA Holdings, directly or indirectly, beneficially owns at least 5% of the Company’s outstanding common stock, DNA Holdings will have the right under the Membership Interest Purchase Agreement to designate one officer and one nominee for election to the Company’s board of directors, and the Company will be required to take reasonably necessary corporate action to appoint such designees, subject to the oversight of the Company’s nominating and governance committee. | ||||||||||||||||
| Investment in DNA X, LLC | $ 1,242 | ||||||||||||||||
| Stock price | $ 5.50 | ||||||||||||||||
| Stock issued during period, value | $ 1,375 | $ 3,850 | $ 13,671 | $ 4,007 | |||||||||||||
| Common stock par value | $ 0.001 | $ 0.001 | |||||||||||||||
| Shares of common stock | 61,111 | 19,444 | |||||||||||||||
| Issuance costs | $ 169 | $ 66 | |||||||||||||||
| Beneficiary ownership limitation percentage | 4.99% | 9.99% | |||||||||||||||
| Commission rate | 3.00% | ||||||||||||||||
| Proceeds from common stock | $ 13,671 | $ 4,007 | |||||||||||||||
| Preferred shares par value | $ 0.001 | $ 0.001 | |||||||||||||||
| Price per share exercisable | $ 4.00 | ||||||||||||||||
| Investor One | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Beneficiary ownership limitation percentage | 9.99% | ||||||||||||||||
| Investor Two | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Beneficiary ownership limitation percentage | 4.99% | ||||||||||||||||
| Warrant [Member] | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Warrants issued | 1,375 | 30,555 | |||||||||||||||
| Warrant exercise price | $ 24.912 | $ 198.00 | $ 13.50 | ||||||||||||||
| Public Offering | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Shares of common stock | 411,111 | ||||||||||||||||
| Shares issued price per share | $ 13.50 | ||||||||||||||||
| Cash fee percentage | 7.00% | ||||||||||||||||
| Legal fees | $ 100 | ||||||||||||||||
| Net proceeds | $ 4,800 | ||||||||||||||||
| DNA Holdings Ventures Inc [Member] | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Convertble notes issued | $ 1,200 | ||||||||||||||||
| [custom:MembershipInterestDescription] | The Membership Interest Purchase Agreement also grants DNA Holdings a put option (the “Put Option”). If at any time prior to June 30, 2026 (the “Put Period”) DNA X does not realize either (i) aggregate trading volume of at least $600,000,000 or (ii) aggregate revenues of at least $1,000,000 per day, DNA Holdings will have the right, during the Put Period, to exchange the shares of common stock issued to DNA Holdings under the Membership Interest Purchase Agreement for the Purchased Interests then held by the Company. To the extent not exercised during the Put Period, the Put Option will terminate upon the expiration of the Put Period. | ||||||||||||||||
| Interest rate percentage | 10.00% | ||||||||||||||||
| Interest rate percentage, default | 20.00% | ||||||||||||||||
| Initial conversion price of convertible note | $ 5.50 | ||||||||||||||||
| Covertible note terms, description | At any time after (i) the termination of the Asset Purchase Agreement or (ii) during the continuance of any event of default under the DNA Note, the conversion price will equal the “Alternate Conversion Price,” which is defined as 80% of the closing price of the Company’s common stock on the Company’s principal trading market on the date of conversion (subject to the same adjustment provisions described above). In addition, if at any time the Depository Trust Company imposes a “chill” on the Company’s shares, the holder may convert the DNA Note at the Alternate Conversion Price while such “chill” is in effect. | ||||||||||||||||
| Convertible note payment terms | the Company is required to redeem the outstanding principal amount of the DNA Note for cash at a price equal to 110% of the then outstanding principal amount, plus accrued but unpaid interest and any other amounts then due under the DNA Note (the “Redemption Amount”), at the closing of such transaction. Notwithstanding the foregoing, the transactions contemplated by the Asset Purchase Agreement do not constitute a Change of Control Transaction under the DNA Note. In lieu of receiving the Redemption Amount, and subject to any required stockholder approval under the rules of the Company’s principal trading market, the holder may elect to convert the DNA Note, in whole or in part, upon a Change of Control Transaction at a price per share equal to the lower of (i) the closing price of common stock on the original issue date of the DNA Note and (ii) the closing price of common stock on the date of consummation of such Change of Control Transaction. | ||||||||||||||||
| Common Stock [Member] | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Stock issued during period, value | $ 12 | $ 4 | |||||||||||||||
| Common stock par value | 0.001 | ||||||||||||||||
| Shares of common stock | [1] | 677,927 | 27,110 | ||||||||||||||
| Common Stock [Member] | ChEF Purchase Agreement | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Stock issued during period, value | $ 500,000 | $ 79 | |||||||||||||||
| Common stock par value | $ 0.001 | ||||||||||||||||
| Shares of common stock | 12,300,000 | ||||||||||||||||
| Placement Agent Warrants [Member] | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Warrants issued | 11,604 | ||||||||||||||||
| Warrant exercise price | $ 13.50 | ||||||||||||||||
| Warrants | Jul. 02, 2030 | ||||||||||||||||
| Warrants adjustment description | The exercise prices of the Placement Agent Warrants are subject to appropriate adjustment in the event of stock dividends, stock splits, stock combinations, reorganizations or similar events affecting the Common Stock. Subject to limited exceptions, a holder of Placement Agent Warrants will not have the right to exercise any portion of its Warrants if the holder (together with such holder’s affiliates, and any persons acting as a group together with such holder or any of such holder’s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, upon election by a holder prior to the issuance of any Warrants, 9.99%) of the shares of common stock then outstanding. At the holder’s option, upon notice to the Company, the holder may increase or decrease this beneficial ownership limitation not to exceed 9.99% of the shares of Common Stock then outstanding. The Purchase Agreement contains customary representations, warranties, and covenants by the Company. | ||||||||||||||||
| Warrant [Member] | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Warrant exercise price | $ 24.9552 | $ 13.50 | |||||||||||||||
| Preferred Stock [Member] | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Preferred shares par value | $ 0.001 | ||||||||||||||||
| Membership Interest Purchase Agreement [Member] | Common Stock [Member] | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Shares issued on acquisitions | 223,201,000 | ||||||||||||||||
| Redeemable common stock | $ 1,228 | ||||||||||||||||
| Sales Agreement [Member] | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Other expenses | $ 258 | ||||||||||||||||
| Sales Agreement [Member] | Common Stock [Member] | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Shares of common stock | 193,405 | ||||||||||||||||
| Proceeds from common stock | $ 8,229 | ||||||||||||||||
| DNA X LLC [Member] | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Membership interests | 100.00% | ||||||||||||||||
| DNA Holdings Ventures Inc [Member] | |||||||||||||||||
| Accumulated Other Comprehensive Income (Loss) [Line Items] | |||||||||||||||||
| Membership interests | 19.99% | ||||||||||||||||
| |||||||||||||||||